In The News: School of Integrated Health Sciences

Practical Neurology

Aducanumab is the first disease-modifying treatment to be approved for Alzheimer's Disease (AD) and the first to target amyloid ß (Aß), which is one of the earliest causative steps in the pathophysiology of AD.

Newswise

The Food and Drug Administration on June 7 approved Aducanumab, which will carry the brand name Aduhelm, as the first new treatment for Alzheimer’s disease in nearly 20 years.

Reuters

The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc’s aducanumab, a decision that will affect the future of Alzheimer’s disease research and treatment and show the agency’s willingness to approve badly needed medicines based on less than definitive data.

Yahoo!

The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc's aducanumab, a decision that will affect the future of Alzheimer's disease research and treatment and show the agency's willingness to approve badly needed medicines based on less than definitive data.

MarketScreener

The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc's aducanumab, a decision that will affect the future of Alzheimer's disease research and treatment and show the agency's willingness to approve badly needed medicines based on less than definitive data.

HealthDay

The U.S. government and nonprofits are replacing drug companies as the main drivers of Alzheimer's disease research, two new studies show.

U.S. News & World Report

The U.S. government and nonprofits are replacing drug companies as the main drivers of Alzheimer's disease research, two new studies show.

Laboratory Equipment

Two articles published by Alzheimer's & Dementia: Translational Research & Clinical Interventions show substantial changes in the focus and funding of clinical trials for Alzheimer's disease therapies. The newly published articles throw a greater spotlight on a decision—now before the U.S. Food and Drug Administration (FDA)—that would potentially bring a new drug therapy to Alzheimer's patients for the first time in nearly 20 years.

Practical Neurology

Nonprofit organizations and public agencies have picked up the slack and are funding increased numbers of clinical trials to drive growth and innovation in an area where there is pressing unmet medical need.

EurekAlert!

Two newly published articles throw a greater spotlight on a decision -- now before the U.S. Food and Drug Administration (FDA) -- that would potentially bring a new drug therapy to Alzheimer's patients for the first time in nearly 20 years.

Insider

Epsom salt is commonly dissolved in baths and used as a home remedy because it is rumored that absorbing magnesium through the skin can provide numerous health benefits.

Wine Enthusiast

As the Black Death, also known as the Black Plague, ravaged Europe and Asia in the mid-1300s, people became increasingly desperate for any iota of respite. Some tried blood-letting. Others opted for rubbing onions—or, in some cases, a chopped snake—directly onto their infected boils.